Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Guy Snir
AddedFeb 15, 2024
UpdatedMay 31, 2026
Guy Snir

Guy Snir

Co-Founder, Clear Genetics

LinkedInThe OrgTwitter

Guy Snir's Career

Clear Genetics
Clear Genetics
Co-Founder
Nest Genomics
Nest Genomics

New York City, NY, US

COO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Guy Snir's Career

Clear Genetics
Clear Genetics
$120k02016
Co-Founder

Leadership at Clear Genetics

Moran SnirMoran SnirCo-Founder & CEO
Motti Shohat M.D.Motti Shohat M.D.Founder

Similar to Clear Genetics

Nest GenomicsNest GenomicsNew York City, NY, USGenomics Softwareest. 2022Nest GenomicsNew York City, NY, US · est. 2022

Nest Genomics: Comprehensive genomic software for clinical care integration and management.

Seed · $9M12
Haplotype LabsHaplotype LabsGenetic Testingest. 2024Haplotype Labsest. 2024

Empowering personalized prevention through genetic risk models on HaploHub SaaS platform.

Seed · $500k1
Genome MedicalGenome MedicalSouth San Francisco, CA, USGenetic Counseling, Telehealthest. 2016Genome MedicalSouth San Francisco, CA, US · est. 2016

Genome Medical: A telegenomics tech firm providing access to genomic-based medicine services.

$120.4M172
Nest Genomics
Nest Genomics
Seed$9M122022New York City, NY, US
COO· C-Suite · Management

Similar to Nest Genomics

GencoveGencoveNew York City, NY, USGenome Sequencing Software, Genomics Platformest. 2015GencoveNew York City, NY, US · est. 2015

Gencove: High-volume, cost-effective genome sequencing software for life-saving discoveries.

$16.2M44
GenomeNextGenomeNextColumbus, OH, USGenomic Analysisest. 2014GenomeNextColumbus, OH, US · est. 2014

GenomeNext offers real-time, automated genomic analysis software for researchers and clinicians.

$1.2M2
Navipoint GenomicsNavipoint GenomicsChicago, IL, USGenomics, Softwareest. 2015Navipoint GenomicsChicago, IL, US · est. 2015

Chicago-based Navipoint Genomics, founded in 2015, specializes in bioinformatics analysis software.

$650k5
GenomenonGenomenonAnn Arbor, MI, USData, Softwareest. 2014GenomenonAnn Arbor, MI, US · est. 2014

Genomenon: Comprehensive genomic evidence provider, aiding in critical biomarker identification.

$32.8M80

People Similar to Guy Snir

Bo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · KakaoJB LEEJB LEECo-Founder · KakaoHong Eun-taekHong Eun-taekCEO · KakaoHae-Jin LeeHae-Jin LeeFounder · NaverKen KnightKen KnightCEO · InvitaeDouglas M. VanOortDouglas M. VanOortBoard Member · NeoGenomics LaboratoriesNick GreenfieldNick GreenfieldFounder · One CodexMegan LimMegan LimCo-Founder · GenomenonGeorge PlattenburgGeorge PlattenburgCo-Founder · ClearGen